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patients infected with severe acute respiratory 
syndrome coronavirus 2 (SARS ‑CoV‑2) , may 
lead to interatrial shunt reversal and worsen‑
ing of hypoxia merely by inversion of the pres‑
sure gradient between the atria. This mechanism 
is arguably more likely than position ‑related 
shunting typical for platypnea ‑orthodeoxia. At 
the same time, the right ‑to ‑left shunt unloads 
the right atrium and is likely to decrease right 
atrial pressure, potentially reducing systemic 
venous congestion. Experience in treating pa‑
tients with pulmonary hypertension indicates 
that sealing interatrial communication does not 
improve their clinical outcomes and, inverse‑
ly, septostomy or implantation of an atrial flow 
regulator6 remains an option for the sickest pa‑
tients without an intracardiac shunt. Therefore, 
PFO closure during the COVID‑19 pandemic can‑
not be routinely recommended, and the clinical 
benefit proposed by Rajendram et al1 remains hy‑
pothetical—even if hypoxia could be alleviated.
We acknowledge the pathophysiological in‑
sights included in the letter and, indeed, agree 
that restrictions in diagnostic procedures must 
be lifted as early as the COVID‑19‑related health‑
care overload decreases—according to local re‑
sources and delivery of services. We have actu‑
ally proposed the statement on identifying ur‑
gent indications for structural heart interven‑
tions, which might be represented not only by pa‑
tients with PFO at high risk of recurrent stroke 
but also the subsets of candidates for transcath‑
eter aortic valve implantation or MitraClip pro‑
cedures. However, benefits and risks (including 
device ‑related thrombosis) must be carefully 
weighed considering that the procoagulant state 
appears to be a major pathophysiologic compo‑
nent of COVID‑19.6 We also believe that con‑
tinuation or suspension of specific lines of di‑
agnostic workup has to be strongly linked with 
the local influence of the COVID‑19 epidem‑
ic upon the healthcare system rather than the 
fact of a pandemic itself.2 Considering the fact 
that high ‑quality medicine requires an individ‑
ualized approach and high ‑level diagnostic in‑
quisitiveness, we appreciate refreshing the still 
uncommonly diagnosed platypnea ‑orthodeoxia 
syndrome to the readers of Kardiologia Polska 
(Kardiol Pol, Polish Heart Journal).
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Authors’ reply Thank you for publishing the 
comment of Rajendram et al1 referring to the re‑ 
cently published scientific statement2 regarding 
the diagnostic workup of patent foramen ova‑
le (PFO) during the coronavirus disease 2019 
(COVID‑19) pandemic. The recommendation of 
possible deferral of elective diagnostic workup 
aimed at screening for PFO, which is a preven‑
tive procedure affecting long  ‑term prognosis af‑
ter cardiogenic embolism, was indeed accepted 
by the Polish experts, in line with the Europe‑
an guidelines.3 Transesophageal echocardiogra‑
phy, as part of diagnostic workup for PFO in par‑
ticular, is a complex, aerosol  ‑generating proce‑
dure with a predictable impact on echocardiogra‑ 
phy laboratory services in the era of COVID‑19..
We acknowledge the comment on a possible 
rare scenario of platypnea  ‑orthodeoxia as a con‑
sequence of PFO. However, this condition is tru‑
ly rare in non  ‑COVID patients (a review by Col‑ 
lado et al4 mentions a prevalence of 2.5% in the 
PFO population, and not 25%, which is in line 
with our own observations), although proper di‑
agnosis is valuable in individual cases of chron‑
ic, uncontrolled hypoxia. This means that, for 
most patients with PFO, a clinical benefit will 
“classically” stem from abated paradoxical em‑
bolism. Interestingly, strokes are not abundant 
during the pandemic.5 Even though a suspicion 
of PFO can be made using computed tomogra‑
phy or magnetic resonance imaging data, the 
critical diagnostic step involves transesopha‑
geal echocardiographic study with a positional 
maneuver, which can be a critical limiting fac‑
tor in the sickest patients including those with 
COVID‑19, especially when ventilated. Impor‑
tantly, extracardiac shunting is an alternative 
explanation beyond the common diagnosis of 
PFO. Importantly, transthoracic echocardiogra‑
phy is routinely suggested in all COVID‑19 pa‑
tients with aggravating hypoxia.3
We deeply regret that the referenced publica‑
tion by Rajendram et al remains to be published 
in Intensive Care Medicine, as we were unable to 
reach it when preparing this response. It is true 
that right ventricular overload or failure, which 
were identified as negative prognostic factors in 
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